Drug Profile
Cyclobenzaprine optimised release - Tonix Pharmaceuticals
Alternative Names: TNX-105Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Krele Pharmaceuticals Inc
- Developer Tonix Pharmaceuticals Holding Corp
- Class Amines; Analgesics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Small molecules
- Mechanism of Action Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Post-traumatic stress disorders
Highest Development Phases
- Discontinued Post-traumatic stress disorders
Most Recent Events
- 15 Nov 2010 TNX 105 will be available for licensing. http://www.tonixpharma.com
- 15 Nov 2010 Investigation in Post-traumatic stress disorder in USA (PO)